The aim of this study was to identify factors associated with the death of patients with COVID-19 pneumonia caused by the novel coronavirus SARS-CoV-2.All clinical and laboratory parameters were collected prospectively from a cohort of patients with COVID-19 pneumonia who were hospitalised to Wuhan Pulmonary Hospital (Wuhan City, Hubei Province, China) between 25 December 2019 and 7 February 2020. Univariate and multivariate logistic regression was performed to investigate the relationship between each variable and the risk of death of COVID-19 pneumonia patients.In total, 179 patients with COVID-19 pneumonia (97 male and 82 female) were included in the present prospective study, of whom 21 died. Univariate and multivariate logistic regression analysis revealed that age ≥65 years (OR 3.765, 95% CI 1.201‒11.803; p=0.023), pre-existing concurrent cardiovascular or cerebrovascular diseases (OR 2.464, 95% CI 1.279‒4.747; p=0.007), CD3⁺CD8⁺T-cells ≤75 cells·μL⁻¹(OR 3.982, 95% CI 1.761‒9.004; p<0.001) and cardiac troponin I ≥0.05 ng·mL⁻¹(OR 4.077, 95% CI 1.778‒9.349; p<0.001) were associated with an increase in risk of mortality from COVID-19 pneumonia. In a sex-, age- and comorbid illness-matched case–control study, CD3⁺CD8⁺T-cells ≤75 cells·μL⁻¹and cardiac troponin I ≥0.05 ng·mL⁻¹remained as predictors for high mortality from COVID-19 pneumonia.We identified four risk factors: age ≥65 years, pre-existing concurrent cardiovascular or cerebrovascular diseases, CD3⁺CD8⁺T-cells ≤75 cells·μL⁻¹and cardiac troponin I ≥0.05 ng·mL⁻¹. The latter two factors, especially, were predictors for mortality of COVID-19 pneumonia patients.

Tuberculosis (TB) is a single infectious agent disease caused by mycobacterium tuberculosis (Mtb) and is the 13th leading cause of death worldwide, usually affecting the lungs and other organs [1]. It is the second leading single cause of death in the future, with an estimated 10 million TB patients globally in 2020 and 10.6 million […]

The clinical efficacy of glucocorticoid therapy on the treatment of patients with Coronavirus Disease 2019 (COVID-19) pneumonia was investigated. This retrospective study showed glucocorticoid therapy did not significantly influence the clinical course of COVID-19 pneumonia, including imaging progress and the time duration for negative transformation of nucleic acid, and glucocorticoid therapy did not significantly influence the outcomes nor the adverse events of COVID-19 pneumonia.